Introduction {#S1}
============

Canine adenovirus-2 (CAV) is a non-human pathogen that causes a mild infectious respiratory disease in dogs known as "kennel cough." CAV was initially studied to develop a vaccine against canine adenoviruses-1, the cause of a severe liver disease in dogs, and proposed as a long-term gene therapy vector for neurological disorders ([@B53]; [@B21]; [@B93]). Since then, CAV has also attracted neuroscientists because of several advantageous properties for studying the anatomy and function of neural circuits ([@B46]; [@B25]). Specifically, it is primarily the retrograde ability of CAV to deliver cargo genes via axon terminals that allow the investigation of the pattern and function of long-range projections ([@B46]). In addition, CAV is useful for studying neural circuits because it has a high neuronal specificity and a strong compatibility with conditional gene expression ([@B53]; [@B93]; [@B46]). Furthermore, CAV is a reliable vector for long-term functional studies, since it mediates stable, lasting gene expression while sustaining low immunogenicity and cytotoxicity levels ([@B53]; [@B21]; [@B93]). This mini-review will summarize the properties that give CAV its edge, highlighting their utility in dissecting the connectivity and functions of neural circuits.

Beneficial Properties of CAV for Circuit Analysis {#S2}
=================================================

Canine adenovirus-2 viruses have been widely utilized in neuroscience due to their capability of infecting axon terminals via a retrograde mechanism and then driving gene expression at the somata. Owing to this retrograde capability, when injected into a brain region, CAV viruses transduce projection neurons which innervate the injection site, in addition to neurons at the injection site ([@B53]; [@B21]; [@B93]; [@B16]). CAV's retrograde capability relies on the coxsackievirus and adenovirus receptor (CAR) ([@B53]; [@B21]; [@B93]). CAR is a cell adhesion molecule necessary for the docking, internalization, endocytosis, and axonal transport of CAV viruses ([@B87]). This receptor is highly enriched at presynaptic sites of neurons, but exists in low density in the somata and dendrites of neurons ([@B108]). This domain-specific CAR expression gives rise to the retrograde transport of CAV, making it a powerful tool for mapping long-range connectivity between brain regions ([@B46]).

Another advantage of CAV for neuroscientists is that CAV vectors exhibit strong tropism, biasing neurons. For example, in the peripheral nervous system, CAV viruses preferentially transduced olfactory sensory neurons instead of the columnar epithelial cells ([@B16]). Moreover, when injected in the central nervous system, CAV strongly infects neurons but not non-neuronal types ([@B93]; [@B16]). The molecular basis for this neuronal tropism is that CAR expression in the brain is primarily, if not exclusively, on neurons but not on astrocytes, oligodendrocytes, endothelium, or meningeal cells ([@B93]; [@B76]). So far, in the central nervous system, CAV vectors have been successfully used to transduce various types of neurons in broad regions of the brain, demonstrating their wide applicability for studying neural circuits ([Table 1](#T1){ref-type="table"}). For example, CAV can transduce a variety of neurotransmitter systems, including, but not limited to, glutamatergic, dopaminergic, GABAergic, noradrenergic, oxytonergic, serotonergic, and cholinergic systems ([Table 1](#T1){ref-type="table"}). Furthermore, CAV has been successfully used in a broad diversity of cortical and subcortical projection pathways ([Table 1](#T1){ref-type="table"}). Even though rodents were used as the animal models in most of CAV applications in [Table 1](#T1){ref-type="table"}, recently, CAV was also successfully used in non-human primates ([Table 1](#T1){ref-type="table"}; [@B65]; [@B13]; [@B27]). These studies validate the applicability of CAV as a gene delivery tool in non-human primates, facilitating the investigation of neural circuits in a more human-relevant model.

###### 

Summary of cell types and circuit pathways where CAV had been used for circuit analysis.

  System                            Circuit                                                                         Effector                                                   References
  --------------------------------- ------------------------------------------------------------------------------- ---------------------------------------------------------- ----------------
  Cholinergic                       DBB → arcuate nucleus                                                           tdTomato                                                   [@B40]
                                    LDTg → VTA                                                                      hM3D(Gq)-mCherry                                           [@B32]
                                    nuclei of Meynert → striatum                                                    GFP                                                        [@B94]
  Dopaminergic                      SNc → striatum                                                                  GFP                                                        [@B94]
                                                                                                                    TH                                                         [@B92]
                                                                                                                                                                               [@B82]
                                                                                                                    RG, TVA-mCherry, GFP, tdTomato, mGFP, SYP-mRuby, GCaMP6f   [@B58]
                                    VTA → NAc                                                                       ArchT-GFP                                                  [@B64]
                                                                                                                    hM3D(Gq)-mCherry,                                          [@B12]
                                                                                                                    hM3D(Gq)-mCherry,                                          [@B47]
                                                                                                                    GFP, NBL10                                                 [@B28]
                                                                                                                    eYFP                                                       [@B81]
                                    VTA → (NAc, mPFC, Amy)                                                          GFP                                                        [@B9]
                                    (VTA, SNc) → Striatum                                                           TH                                                         [@B43]
                                    VTA → (NAc, BLA)                                                                                                                           [@B30]
                                    Midbrain human organoid                                                         GFP                                                        [@B15]
                                                                                                                                                                               [@B91];
  GABAergic                         POA → (TMN, PFC)                                                                GFP, RG,TVA-mCherry, mGFP, SYP-mRuby                       [@B22]
                                    mPOA → (PAG, PVN, Amy, VTA)                                                     ZsGreen, mCherry, myrGFP, RG, TVA-mCherry                  [@B51]
                                    CeA → (PCRt, PAG)                                                               ChR2-mCherry, GFP                                          [@B37]
                                    CeA→ PAG                                                                        RG, ArchT-GFP                                              [@B105]
                                    Cervical → lumbar                                                               tdTomato, DTR, SynTag                                      [@B85]
  Glutamatergic                     PLC → (NAc, Amy)                                                                GCaMP6f, GFPL10                                            [@B68]
                                    PLC → PVT                                                                       hM3D(Gq)-mCherry, hM4D(Gi)-mCherry                         [@B17]
                                    GC → BLA                                                                        tdTomato                                                   [@B56]
                                    (HPC, mPFC) → LS                                                                GFP, hM3D(Gq)-mCherry, hM4D(Gi)-mCherry                    [@B73]
                                    Cervical → lumbar                                                               tdTomato, DTR, SynTag                                      [@B85]
                                    mPFC → PAG                                                                      ChR2-YFP                                                   [@B98]
                                    mPFC → NAc                                                                      hM3D(Gq)-mCherry, ChR2-eYFP                                [@B7]
                                    mPFC → RE                                                                       hM4D(Gi)-mCherry                                           [@B80]
                                    mPFC → MDT; MDT→ mPFC                                                           hM4D(Gi)-mCherry                                           [@B2]
                                    (contra. mPFC, MDT, HPC) → mPFC                                                 hM3D(Gq)-mCherry, tdTomato                                 [@B66]
                                    PFC → (NAc, PVT)                                                                GCaMP6; eYFP, ChR2-eYFP, eNpHR-eYFP                        [@B71]
                                    ACC → HPC                                                                       eNpHR, eYFP                                                [@B79]
                                    (ORBvl, VC, RSP, contra. ACC) → ACC                                             tdTomato                                                   [@B20]
                                    OFC → striatum                                                                  ChR2-eYFP                                                  [@B41]
                                    VC → NOT/DTN                                                                    tdTomato, DTR-GFP                                          [@B62]
                                    VC → SC                                                                         tdTomato                                                   [@B107]
                                    ACtx → IC                                                                       GCaMP6s                                                    [@B6]
                                                                                                                    ChR2-mCherrry                                              [@B103]
                                    (ACtx, Ath) → striatum                                                          tdTomato, ChR2                                             [@B78]
                                    MC → (contra. MC, Me) (OB, HPC, ACtx, Me) → LC                                  RG, GFP, TVA-mCherry                                       [@B88]
                                    MC → (Spinal cord, Contra. MC)                                                  GCaMP6s, tdTomato                                          [@B49]
                                    EC → DG                                                                         ChR2-YFP, tdTomato                                         [@B59]
                                    Periform cortex → (OB, CoA)                                                     ChR2-YFP                                                   [@B26]
                                    Multiple cortices → BPN                                                         eGFP                                                       [@B95]
                                    PBNl → (CeA, MdD)                                                               hM4D(Gi)-mCherry                                           [@B18]
                                                                                                                    hM4D(Gi)-mCherry, mCherry                                  [@B3]
                                                                                                                    hM3D(Gq), PLAP                                             [@B8]
                                    vMT → (BLA, mPFC, NAc)                                                          hM3D(Gq)-mCherry                                           [@B86]
                                    BLA → mPFC                                                                      tdTomato                                                   [@B99]
                                                                                                                    ChR2-eNpHR-venus                                           [@B89]
                                                                                                                    ChR2-mRubby, DsRed, GFP                                    [@B60]
                                    BLA → (NAc, CeA, HPC)                                                           ChR2-eYPF                                                  [@B11], [@B10]
                                                                                                                    eNpHR-eYFP, eYFP                                           [@B70]
                                    (Multiple cortices, SNc, basal nuclei of Meynert, Thalamic nuclei) → Striatum   GFP, LRRK2                                                 [@B65]\*
                                    (DCN, IO, VN, NRTP, etc.) → Cb                                                  GFP                                                        [@B27]\*
                                    Pontine nuclei → vermis lobule                                                  GFP, RG, TVA-mCherry                                       [@B100]
                                    LH → LHb                                                                        hM4D(Gi)-mCherry, tdTomato                                 [@B57]
                                    CLA → mPFC                                                                      tdTomato                                                   [@B1]
                                    HPC → (CeA, BLA)                                                                ChR2-eYFP, RG, TVA, ArchT-GFP, GFP, eNpHR-eYFP             [@B105]
                                    POm → M1                                                                        RG, GFP, TVA-mCherry                                       [@B67]
                                    PVT → NAc                                                                       GCamP6s                                                    [@B72]
                                    preBötC → LC                                                                    DTR                                                        [@B106]
  Noradrenergic                     LC → spinal cord                                                                ChR2-mCherry                                               [@B61]
                                    LC → (spinal cord, PFC)                                                         PSAM-eGFP                                                  [@B42]
                                    LC → (ACtx, Cb, HPC, Me, OB)                                                    RG, GFP, TVA-mCherry                                       [@B88]
                                    LC → (BLA, mPFC)                                                                ChR2, mAG1, SYP-mCherry, ArchT-tdTomato                    [@B97]
  Oxytonergic                       PVN → SON                                                                       eGFP; SYP-GFP ChR2-mCherry, hM4D(Gi)-mCherry               [@B29]
  Serotonergic                      DRN → Amy                                                                       5-HT1b, GFP                                                [@B63]
                                    Raphe nuclei → NTS                                                              Knockout Tph2                                              [@B104]
  Non-canonical neurotransmitters   PVT → CeA                                                                       hM4D(Gi)-mCherry                                           [@B74]
                                    CeA → LC                                                                        DTX                                                        [@B4]
  Periphery                         Motor neurons → craniofacial muscle                                             GFP                                                        [@B13]\*
                                    NG → gut                                                                        GFP, rM3D(Gs)-mCherry                                      [@B36]

The citations in this table serve as examples of each type of studies.

\*

Non-human primate studies.

Among a number of retrograde viruses (for example, rabies, lentivirus, and rAAV2-retro), what makes CAV viruses unique is their carrying capacity and physical size. In fact, CAV is the second largest retrograde virus with a 30--36 kb cloning capacity and ∼90 nm diameter, leading over rabies (1--3 kb) and lentivirus (9 kb) by 10- and 3-fold, respectively ([@B96]). The large carrying load of CAV allows flexible, diverse, and creative design of cargo genes, which is particularly useful when dissecting neural circuits. For example, one can combine a variety of genes such as optogenetic tools, genetically encoded indicators of neuronal activity, fluorophores, large promoters, recombinases, LoxP/Flp sequences, and so on in one CAV vector ([Figure 1A](#F1){ref-type="fig"}). Such combinations allow one to selectively label neurons according to cell type and/or projection, and they also facilitate efforts to monitor and perturb neural activity simultaneously ([@B94]; [@B46]). Moreover, the large physical size of CAV provides advantages for neuroscientists performing stereotactic injections into small nuclei. CAV viruses (∼90 nm in diameter) remain near the injection site compared to smaller adeno-associated viruses (AAV) (22 nm in diameter). For instance, 0.25--0.5 μl of CAV spread on average by 200 μm from the center of the injection site, while 0.25 μl of rAAV2-retro spread four times more ([@B88]; [@B95]). This restricted diffusion of CAV is useful when studying small structures, such as the complex of the nucleus of the optic tract and the dorsal terminal nucleus (NOT/DTN) ([@B62]), PAG ([@B24]) or CLA ([@B23]). It is worth noting that CAV cannot be injected with iontophoresis, which is commonly used to confine the spread of electrically charged AAV viruses ([@B33]), because the coat proteins of CAV are almost electrically neutral (10 times less charged than AAV viruses) ([@B48]; [@B21]).

![Canine adenovirus type 2 (CAV-2) combined with genetic approaches allows a variety of experimental designs for circuit analyses. **(A)** Venn diagram of two intersectional methods: part **(A1)** provides projection-specific expression using two conditions, while part **(A2)** provides cell-type and projection-specific expression using three conditions. **(B)** The simplest experimental design that labels both local (area c) and projection neurons (areas a and b). **(C)** The schematics of experimental designs for projection-specific expression with the help of Cre (+) recombinase. **(D)** The schematics of experimental designs for cell-type and projection-specific expression with the help of both Cre (+) and Flp (\*) recombinases. **(E)** The schematics of transsynaptic experimental design which selectively labels the input onto projection-specific neuronal population defined by retrograde CAV-Cre. **(F)** The schematics of transsynaptic experimental design which selectively labels the input onto cell-type and projection-specific neuronal population.](fnmol-13-00009-g001){#F1}

For CAV to be an effective gene delivery tool, it should provide lasting, stable gene transduction. Indeed, to determine its viability for long-term experiments, [@B94] injected a CAV vector carrying green fluorescent protein (GFP) gene into multiple sites of the striatum in rats and indeed observed a high level of green fluorescent protein expression lasting for more than a year. In addition to rodents, CAV transduction led to a stable long-term transgene expression in a human stem-cell-derived 3D neural *in vitro* model ([@B91]), demonstrating its promise for functional experiments. Moreover, an ideal gene delivery vector should also avoid host immune responses and cytotoxicity. Indeed, CAV viruses are not human pathogens and do not induce significant cellular infiltration in rat brains ([@B94]), nor in rhesus monkeys, unless abnormally high titers are used ([@B13]). Even a pre-existing immunity against human adenoviruses does not significantly affect CAV transduction ([@B50]; [@B53]; [@B44]). To further minimize the possible disruptions to normal neural processes caused by viral infection, CAV viral vectors were further engineered. For instance, the early region 1 (E1) gene, which is important for DNA replication, was deleted from CAV genome ([@B50]). The E1-deleted CAV is replication incompetent ([@B19]; [@B31]) and thus causes negligible immune response in humans, non-human primates, and rodents at experimentally relevant titers ([@B53]; [@B75]; [@B13]; [@B55]). Consequently, a large number of neurons can be transduced by E1-deleted CAV without being recognized and eliminated by immune cells ([@B53]; [@B94]; [@B75]; [@B55]).

Another line of evidence supporting the low cytotoxicity of CAV came from studies of neuronal morphology. CAV infection did not change the shape of the somata, the axonal arborization, the number of synaptic buttons, nor did it alter the ultrastructures of transduced neurons ([@B91]; [@B60]). Interestingly, even with high multiplicity of infection (∼1,000 viral genomes/cell -- which is 10--50× higher than normal; [@B39]), CAV did not disrupt the neuronal development of cultured cells, in contrast to both AAV and lentivirus ([@B77]). The long-lasting gene expression and negligible impact on the physiology of neurons make CAV a competent vector when expressing effectors for functional analyses. Indeed, CAV-Cre mediated the expression of effectors for chemogenetics ([@B7]; [@B84]; [@B2]; [@B80]), genetic ablation ([@B62]), and calcium imaging ([@B71], [@B72]) for an intermediate time window, ranging from 2 weeks to a couple of months. Beyond 2 months, CAV can steadily express effectors for longer term functional analysis. For examples, CAV-mediated transduction of ChR2 in LC neurons remained stable for 6 months and was used to manipulate the sleep--wake transition of mice ([@B61]). These experiments demonstrated the applicability of CAV for studying the physiology of neural circuits, with minimal effects on cellular health and circuit integrity.

Applications {#S3}
============

Canine adenovirus-2 is a powerful tool for mapping the input and output innervations of various types of projection neurons, and for recording or manipulating their activity. The simplest application of CAV involves transducing presynaptic and local neurons with either a fluorophore or an effector ([Figure 1B](#F1){ref-type="fig"}). For instance, [@B61] revealed the existence of two separate neuronal populations in the rodent LC by injecting CAV carrying either red or green fluorophore in one of two known postsynaptic targets of LC neurons. Similarly, this straightforward experimental design was also used in non-human primates to express fluorescent proteins in neural pathways of interest, including motor neurons that innervate craniofacial muscles and midbrain neurons that project to the Cb ([@B13]; [@B27]). This simple experimental design works well to tag projection neurons innervating a target of interest. However, on its own, CAV cannot be used to selectively target a single pathway, nor to report the anatomical origin of observed fluorescent axonal fibers. This limitation arises from the ambiguity that CAV can retrogradely transduce projection neurons non-specifically in any presynaptic region, as well as neurons near the injection site through their dendrites and somata, which express low but significant levels of CAR ([@B16]; [@B108]; [@B27]) and through their local axons ([Figure 1B](#F1){ref-type="fig"}). To remove this ambiguity, a variety of conditional gene expression paradigms have been developed, taking advantage of DNA recombinases ([Figures 1C--F](#F1){ref-type="fig"}; [@B69]). For instance, CAV viruses carrying the Cre recombinase gene can be injected into a target of interest, in addition to a second injection of AAV viruses carrying a target gene flanked by loxP sequences, injected into a potential presynaptic site ([Figure 1C](#F1){ref-type="fig"}). Cre recognizes loxP and conditionally turns on (or off) the loxP-flanked target gene ([@B69]). By combining CAV's retrograde capability with Cre-loxP conditional expression, this intersectional method ([Figure 1A](#F1){ref-type="fig"}) labels specific neuronal projections ([@B89]; [@B74]; [@B7]; [@B62]; [@B24]). This design was used to identify a corticofugal pathway from the VC to the brainstem and to ablate it exclusively ([@B62]), demonstrating the potential of CAV in projection pathway specific circuit analysis ([@B46]). The design in [Figure 1C](#F1){ref-type="fig"} was ingeniously modified to express genes in an even more selective way ([Figure 1D](#F1){ref-type="fig"}). In this new method, a second conditional expression system Flp--Frt (Flp, flippase recombinase; Frt, Flp recombinase target sequences) ([@B83]) is added so that a Cre transgenic mouse line is used to restrict the expression of target genes in molecularly defined cell types, while Flp carried by CAV selects projection pathways. Therefore, both projection specificity and cell-type specificity are accomplished simultaneously with this clever design. This intersectional method was used in a few studies to lay out the projections of specific types of neurons ([@B88]; [@B22]; [@B47]). For example, [@B22] examined the output pattern of GABAergic neurons in the preoptic area projecting to the TMN pathway.

The above intersectional strategy is not limited to the applications of mapping direct monosynaptic connections between two brain regions (a→b) ([Figures 1C,D](#F1){ref-type="fig"}). Instead, it can also be applied to trace more complex neural circuits involving disynaptic connections (a→b→c), with the help of EnvA-pseudotyped, glycoprotein (G)-deleted rabies viruses (RVdG) ([Figures 1E,F](#F1){ref-type="fig"}). Wild-type rabies viruses are capable of transsynaptic transport, which allows them to move from postsynaptic neurons, via synapses, to presynaptic neurons ([@B101]). The engineered RVdG, however, loses this capability unless the target postsynaptic neurons (the so-called starter cells) express both avian sarcoma leukosis virus receptor (TVA) and G ([@B101]). TVA receptor is required for EnvA-pseudotyped rabies to enter starter cells, and G protein is necessary for rabies's transsynaptic capability ([@B101]). The expression of those two proteins in starter cells complements RVdG and allows it to infect the starter cell's presynaptic neurons ([@B101]). Making use of this elegant design, the disynaptic tracing outlined in [Figures 1E,F](#F1){ref-type="fig"} occurs in two steps: (1) the intersectional method detailed previously, which uses CAV-Cre to selectively express TVA and G protein in starter cells, defining the output projections (b→d); (2) the retrograde transsynaptic transport of RVdG determines the input innervation of starter cells (a→b). These disynaptic tracing methods have been used to determine the pattern of inputs received by individual noradrenaline populations in LC defined by their output target and cell type ([@B88]). This study benefited greatly from CAV's large size and low diffusion rate, which confines CAV-Cre within the size of small brain regions of interest ([@B88]). In sum, CAV is most widely used to carry recombinases or recombinase-dependent constructs ([Table 1](#T1){ref-type="table"}), making it a powerful retrograde vector to investigate both monosynaptic and disynaptic connections within a neural circuit.

Even though most of our examples of CAV and intersectional method applications concerned circuit anatomy, the same intersectional approaches can be easily tweaked for functional analyses or molecular profiling. For instance, a variety of effector molecules have been conditionally expressed for either chemogenetics ([@B12]; [@B7]; [@B2]; [@B32]; [@B80]; [@B47]), optogenetic ([@B29]; [@B61]), projection-specific genetic ablations ([@B104]; [@B62]), optical calcium imaging ([@B71], [@B72]), and molecular profiling ([@B28]). Furthermore, the ability of CAV to seamlessly deliver and selectively express effectors can be paired with classical techniques, such as slice or *in vivo* electrophysiology ([@B29]; [@B61]), and a variety of behavior paradigms ([@B62]; [@B47]). Pairing these techniques with CAV and intersectional methods enables a wide range of combinations, allowing substantial versatility and creativity in experimental designs. It should be noted that, regardless of the vector used, long-term overexpression of Cre recombinase can be toxic ([@B90]; [@B14]; [@B102]; [@B34]; [@B38]; [@B45]; [@B54]), and therefore, precautions are needed when Cre is used in functional assays.

CAV Limitations and Future Directions {#S4}
=====================================

In spite of the great success of CAV in the above studies, one should be cautious of the limitations of this tool and aware of the caveats when interpreting experimental results. For instance, there is evidence that CAV transduction biases some types of neurons or pathways ([Table 2](#T3){ref-type="table"}), likely due to varying CAR expression level in different types of neurons ([@B52]; [@B35]). For example, when examining the projection from basolateral Amy (BLA) to mPFC, [@B89] found that CAV and herpes simplex virus 1 retrogradely labeled largely non-overlapping subpopulations of BLA neurons when injected into the mPFC area, indicating that CAV transduced only a part of this projection population. In addition, the strong tropisms of CAV for particular cell types over others was also observed in corticocortical projections. In particular, CAV injected in the ACC of mice preferentially transduced neurons in layer 5 of the primary VC; in contrast, other retrograde viruses, such as engineered rabies and rAAV2-retro, injected in the same cortical area transduced neurons across multiple layers of the primary VC ([@B20]). Therefore, when using CAV to map unknown connectivity, one must be cautious when drawing conclusions about negative results, as a lack of evidence for connectivity could be alternatively explained by CAV tropism.

###### 

Summary of cell type or projection-specific CAV tropism.

  System          Circuit                                  Comparison                                                                     References
  --------------- ---------------------------------------- ------------------------------------------------------------------------------ ------------
  Glutamatergic   BLA → mPFC                               CAV: bias medial BLA cells HSV: bias lateral BLA cells Retro-beads: no bias    [@B89]
                  (contra. ACC, ORBvl, VISal, RSP) → ACC   CAV: bias L5 cells Retro-AAV: bias L2/3 cells Rabies: both L5 and L2/3 cells   [@B20]
                  Cortices → BPN                           CAV: low efficiency rAAV2-retro: high efficiency Fluro-Gold: high efficiency   [@B95]
                  OFC → VS                                 CAV: low efficiency CAV + AAV-CAR: high efficiency                             [@B60]
                  BLA → mPFC                               CAV: low efficiency CAV + AAV-CAR: high efficiency                             [@B47]
  Dopaminergic    (VTA, DNC) → DLS                         CAV + AAV-CAR: high efficiency rAAV2-retro: low efficiency                     
                  VTA → NAc                                CAV = CAV + AAV-CAR: high efficiency rAAV2-retro: low efficiency               

A second limitation of CAV is its efficacy of retrograde transduction. While sufficient to drive gene expression for both anatomical and functional experiments ([Table 1](#T1){ref-type="table"}), CAV viruses are not quite comparable in infectivity and retrograde transport to other retrograde viruses such as rAAV2-retro and rabies virus ([@B5]; [@B95]; [@B20]; [Table 2](#T3){ref-type="table"}). For example, in the corticopontine circuit, rAAV2-retro viruses injected into the basal pontine nuclei transduced 22 times more layer 5 projection neurons in the cortex than the CAV viruses ([@B95]). As such, a more efficient CAV virus with little tropism would be a great improvement, since it could facilitate the detection of sparse projections and increase the strength of functional manipulations, facilitating the detection of subtle physiological or behavioral effects.

To improve the efficiency of CAV or even overcome its tropism against some neuronal types, an elegant receptor complementation strategy was recently developed, focusing on CAR, a key receptor molecule for the retrograde capability of the CAV ([@B60]). In this method, the CAR receptor was virally expressed in candidate projection neurons, which in turn facilitated the retrograde transduction of those targeted neurons by CAV carrying Cre recombinase ([@B60]). This strategy increased the efficacy of CAV retrograde transport in the BLA-to-mPFC pathway, where CAV has limited infectivity in control animals ([@B60]). This strategy is also potentially useful to circumvent the tropism of other retrograde viruses, providing CAR/CAV combination a significant advantage over rAAV2-retro and rabies ([@B60]). For example, rAAV2-retro viruses showed marginal retrograde transduction of dopaminergic neurons in the VTA and SNc (VTA/SNc) that project to dorsolateral striatum (DLS) ([@B95]). By virally expressing the CAR receptor in VTA/SNc, the number of dopaminergic neurons that were retrogradely infected by the CAV injected into the DLS was approximately nine times larger than when rAAV2-retro was used. Nevertheless, the applicability and limitations of this receptor complementation strategy in other cell types and pathways need to be explored and validated ([@B47]).

Conclusion {#S5}
==========

In summary, the unique characteristics of CAV make it an intriguing choice for neuroscientists. CAV vectors complement the toolbox of retrograde viruses, which can be used to reveal the connectivity and physiology of neural circuits. In particular, due to low toxicity, minimal immunogenicity, and stable gene expression, CAV is ideal for long-term functional analyses of brain circuits. Moreover, the capability of combining CAV with conditional expression and transsynaptic tracing makes it a promising tool to study circuits in cell- and/or projection-type specific manners. Finally, the success of the CAR receptor complementation strategy provides a method to circumvent the limitations of CAV, opening a new era for circuit analysis. Needless to say, CAV will continue to facilitate the long-standing quest to ultimately understand the biological substrates and logics of brain functions.
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ACC

:   anterior cingulate cortex

ACtx

:   auditory cortex

Amy

:   amygdala

Ath

:   auditory thalamus

BLA

:   basolateral amygdala

BPN

:   basal pontine nucleus

Cb

:   cerebellum

CeA

:   central amygdala

CLA

:   claustrum

CoA

:   cortical amygdaloid nucleus

Contra.

:   contralateral

DBB

:   diagonal band of brocca

DCN

:   deep cerebellar nuclei

DG

:   dentate gyrus

DMH

:   dorsomedial hypothalamus

DRN

:   dorsal raphe nucleus

EC

:   entorhinal cortex

GC

:   gustatory cortex

HPC

:   hippocampus

IC

:   inferior colliculus

IO

:   inferior olive

LC

:   locus coeruleus

LH

:   lateral hypothalamus

LHb

:   lateral habenula

LS

:   lateral septum

LTDg

:   laterodorsal tegmentum

M1

:   primary motor cortex

MC

:   motor cortex

MdD

:   reticular formation

MDT

:   medial dorsal thalamus

Me

:   medulla

mPFC

:   medial prefrontal cortex

mPOA

:   medial preoptic area

NAc

:   nucleus accumbens

NG

:   nodose ganglia

NOT/DTN

:   complex of nucleus of optic tract and dorsal terminal nucleus

NRTP

:   nucleus reticularis tegmenti pontis

NTS

:   nucleus tractus solitaries

OB

:   olfactory bulb

OFC

:   orbitofrontal cortex

ORBvl

:   ventrolateral orbital cortex

PAG

:   periaqueductal gray

PBNl

:   lateral parabrachial nucleus

PCRt

:   parvocellular reticular formation

PFC

:   prefrontal cortex

PLC

:   prelimbic cortex

POm

:   posterior medial thalamic nucleus

preBötC

:   preBötzinger complex

PVN

:   hypothalamic paraventricular

PVT

:   paraventricular thalamus

RE

:   thalamic nucleus reuniens

RSP

:   retrosplenial cortex

SC

:   superior colliculus

SNc

:   substantia nigra pars compacta

SON

:   supraoptic nuclei

STN

:   subthalamic nucleus

TMN

:   tuberomammillary nucleus

VC

:   visual cortex

vMT

:   ventral midline thalamus

VTA

:   ventral tegmental area.
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